Table 2.
Detection of the various TGCT histological subtypes using the miR-371a-3p and RASSF1AM as serum biomarkers.
| Variables | miR-371a-3p Positivity (n, %) |
|---|---|
| All TGCTs | 84/98 (85.7%) |
| Pure seminoma * | 19/21 (90.5%) |
| Pure embryonal carcinoma | 14/15 (93.3%) |
| Pure postpubertal-type yolk sac tumor | 2/2 (100%) |
| Pure choriocarcinoma | 1/1 (100%) |
| Pure postpubertal-type teratoma | 4/9 (44.4%) |
| Mixed tumor # | 44/50 (88.0%) |
| GCNIS | 3/5 (60.0%) |
| Variables | RASSF1AM Positivity (n, %) |
| All TGCTs | 85/98 (86.7%) |
| Pure seminoma * | 19/21 (90.5%) |
| Pure embryonal carcinoma | 13/15 (86.7%) |
| Pure postpubertal-type yolk sac tumor | 2/2 (100%) |
| Pure choriocarcinoma | 1/1 (100%) |
| Pure postpubertal-type teratoma | 8/9 (88.9%) |
| Mixed tumor # | 42/50 (84.0%) |
| GCNIS | 5/5 (100%) |
* includes one patient with very high AFP levels, treated as a non-seminoma. # includes the patient with a synchronous bilateral tumor (mixed tumor + teratoma). Abbreviations: GCNIS—germ cell neoplasia in situ; RASSF1AM—hypermethylated RASSF1A; TGCT—testicular germ cell tumor.